PozLab Joins Selvita, Enhancing Contract Manufacturing Services

• Selvita S.A. has completed the acquisition of PozLab, a CDMO located in Poznan, Poland with expertise in drug product development and small pilot plant capabilities.

• The acquisition expands Selvita’s capabilities in the pharmaceutical research sector, particularly in small molecule drug manufacturing for early-stage clinical trials.

Selvita has announced the completion of its strategic acquisition of PozLab. This acquisition took place on July 5, 2024. PozLab is a Contract Development and Manufacturing Organization (CDMO) based in Poznan, Poland, offering drug product development services and small pilot plant capabilities.

PozLab holds a Good Manufacturing Practice (GMP) license for the manufacture of medical and investigational products. The company currently employs over 80 subject matter experts and operates from state-of-the-art R&D facilities in Poznan, which offer approximately 1700 m2 of research space.

The acquisition of PozLab is a strategic move by Selvita to expand its capabilities in the pharmaceutical research sector. With this acquisition, Selvita not only broadens its portfolio but also adds valuable competencies in analytical, formulation, and process development, followed by microbiological testing.

Bogusław Sieczkowski, President of the Management Board of Selvita, expressed his enthusiasm about the acquisition. He said, “I would like to extend a very warm welcome to our new colleagues in Poznan. It’s wonderful to have them on board and I am looking forward to all the synergies this new relationship will bring.”